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ABSTRACT
Myeloid forms of leukemia would seem to be an ideal disease for investigators wishing to develop targeted
immunotherapy because the leukemia is derived from antigen-presenting cells and because clinical data have
demonstrated that there is potent T-cell immunity to chronic myeloid leukemia when donor lymphocyte
infusions are used to treat relapse after transplantation. However, clinical vaccine studies have had to wait for
the identification of specific antigens, some of which have recently been identified, and for a more complete
understanding of basic tumor immunology. Here we review relevant fundamental T-cell biology, the nature of
some important leukemia-associated antigens, and the preliminary results from recent clinical vaccine trials for
leukemia. Although these studies are still early, they offer evidence that effective immunity to leukemia is
possible after vaccination, thus setting the stage for future combined therapies.
© 2006 American Society for Blood and Marrow Transplantation
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It has long been recognized that allogeneic stem
ell transplantation conveys a potent graft-versus-leu-
emia (GVL) effect and a graft-versus-tumor (GVT)
ffect against some solid tumors. Nonmyeloablative
tem cell transplantation strategies, in particular, rely
n donor-mediated GVL and GVT to induce and
aintain remission because the lower doses of chemo-
herapy that are used are not as effective as the more
raditional high-dose myeloablative chemotherapy at
ontrolling the disease. The use of donor lymphocytes
o induce remission after relapse of chronic myeloid
eukemia (CML) and acute myeloid leukemia (AML)
nd the high relapse rate seen after T cell–depleted
ransplantation suggest that donor T lymphocytes are
he principal mediators of GVL/GVT, although do-
or natural killer cells also contribute to GVL after
aploidentical transplantation. Graft-versus-host dis-
ase (GVHD), also mediated by donor T cells, re-
ains the major obstacle that must be overcome be-
ore we can exploit the full potential of GVL.
evertheless, if we understood the nature of the tar-
et antigens of GVL, we could design rational vaccine
trategies that could increase GVL. Our challenge is
o understand the mechanism of GVL and GVHD, to f
B&MTetermine whether these phenomena are separable,
nd to understand whether the T cells that mediate
ach of them can be identiﬁed and manipulated to
roduce a more favorable outcome after transplanta-
ion.
ACKGROUND
To learn whether we can separate GVL from
VHD, we must ﬁrst consider relevant clinical ob-
ervations that give us clues as to the nature of GVL.
he most compelling evidence of T cell–mediated
VL comes from studies of donor lymphocyte infu-
ion (DLI) to treat relapsed CML. Lymphocyte trans-
usion from the original bone marrow donor induces
oth hematologic and cytogenetic responses in ap-
roximately 70% to 80% of patients with CML in
hronic phase [1]. AML is also susceptible to the GVL
ffect, with 15% to 40% of patients obtaining remis-
ion with DLI alone [2]. In the case of CML, a
omplete cytogenetic response is usually obtained be-
ween 1 and 4 months after DLI [3], and approxi-
ately 80% of responders will achieve reverse tran-
criptase-polymerase chain reaction (PCR) negativity













































































































1(9;22) translocation found in CML] within a mean of
months [3]. In contrast, acute GVHD develops
ore rapidly, often within days or weeks after success-
ul engraftment. It is interesting to note that, like com-
lete remission, chronic GVHD develops over several
onths and is most closely correlated with an increased
isease-free survival. Moreover, chronic GVHD often
esembles autoimmune diseases such as scleroderma and
rthritis. Whereas signiﬁcant GVHD occurs in 50% of
ost patients treated with DLI and disease response
ccurs in 90% of CML patients, 55% of patients who do
ot experience GVHD also have a disease response [4,5].
rom these observations, we can conclude that GVL
evelops slowly, generally over 2 to 6 months, and like
ost other therapies it works best when the patient
as minimal residual disease. This might be the result
f a low precursor frequency of GVL-producing T
ells in the donor repertoire, which require enough
ime to proliferate to sufﬁcient numbers in the recip-
ent. Data from clinical trials that used large numbers
f tumor-inﬁltrating lymphocytes to successfully treat
elanoma patients support this conclusion. Further-
ore, the clinical data summarized above show that
VL is separable from GVHD in some patients. To-
ether, these observations suggest the potential to
anipulate donor T-cell immunity in favor of GVL.
Animal models have established that both donor
D4 and CD8  T-cell antigen receptor (TCR)–
ositive T cells can mediate GVL, and clinical studies
f T cell–depleted stem cell transplants have con-
rmed the central role of  T cells.
These CD4 and CD8  T cells recognize
eptide antigens in the context of class II and class I
ajor histocompatibility complexes (MHC), respec-
ively. Peptides derived from cytoplasmic proteins that
re 8 to 11 amino acids long bind in the groove of class
MHC molecules and are transported via the endo-
lasmic reticulum to the cell surface. Larger peptides,
ypically 12 to 18 amino acids long, that are derived
rom the processing of extracellular proteins bind class
I MHC molecules and are presented to T cells on the
ell surface. Both peptide/MHC I and peptide/MHC
I are recognized by the heterodimeric  TCR on
D8 or CD4 T lymphocytes, respectively, with weak
fﬁnity and rapid off rates. Points of contact between
he TCR and the peptide/MHC surface include sur-
ace amino acids contributed by the 2 -helical do-
ains of the MHC molecule that ﬂank the peptide
ntigen-binding pocket, as well as amino acids from
he peptide itself. In the case of MHC-matched alloge-
eic transplantation, single–amino acid differences in
imilar peptides, most often the result of nonsynony-
ous polymorphic differences in DNA between donor
nd recipient, account for much of the alloreactivity.
Our understanding of the nature of antigen-spe-
iﬁc T-cell responses has been greatly improved by
he discovery that antigen-speciﬁc TCRs can be re- v
4ersibly labeled with soluble peptide/MHC tetramers
6]. Peptide antigen, 2-microglobulin, and the MHC
heavy chain are folded together and, via a biotinyla-
ion signal sequence at the C-terminus of the MHC I
eavy chain, are linked covalently to streptavidin in a
:1 molecular ratio. When the streptavidin molecule is
inked to a ﬂuorescent dye such as phycoerythrin, the
esulting peptide/MHC tetramers can be used to
dentify antigen-speciﬁc T cells by ﬂuorescence-acti-
ated cell-sorting analysis because of their higher
inding avidity to the cognate TCR. By using tet-
amers, it has been determined that up to 45% of all
eripheral circulating T cells may be speciﬁc for a
ingle dominant antigen at the height of an immune
esponse to Epstein-Barr virus infection [7], and sim-
lar dominance may be seen during other viral infec-
ions [8,9]. Tetramers have also been used to study
mmune responses to tumor antigens [10], and they
ave also aided in their discovery [11].
ANDIDATE VACCINE ANTIGENS
Various candidate antigens have been identiﬁed in
eukemia immunity. For instance, tissue-restricted mi-
or histocompatibility antigens (mHAs) that are de-
ived from proteins expressed only in hematopoietic
issue have been shown to be the targets of alloreactive
cells [12-16]. These mHAs often result from poly-
orphic differences between donor and recipient in
he coding regions of peptide antigens that bind
ithin the groove of MHC molecules and are recog-
ized by donor T cells. Recently, however, a newly
escribed mHA was found to result from differential
xpression in donor and recipient as a result of a gene
eletion [12]. Heterologous T-cell clones that dem-
nstrate alloreactivity toward mHAs have been estab-
ished from patients with severe GVHD after bone
arrow transplantation with an HLA-matched donor
17-20]. Some of these mHA-speciﬁc cytotoxic T lym-
hocyte (CTL) clones react only with hematopoietic-
erived cells, thus suggesting tissue speciﬁcity [19]
nd, therefore, potentially shared antigens on leuke-
ia. In one study, GVHD correlated closely with
ifferences in the minor antigen HA-1 in HLA-iden-
ical sibling transplantations [21]. Expression of 2 hu-
an mHAs, identiﬁed as HA-1 and HA-2, is conﬁned
o hematopoietic tissues, and HA-2 was identiﬁed as a
eptide derived from the non–ﬁlament-forming class I
yosin family by using mHA-reactive CTL clones to
creen peptide fractions eluted from MHC class I
olecules [14]. It is yet unclear whether CTLs spe-
iﬁc for the minor antigens identiﬁed thus far con-
ey only leukemia-speciﬁc immunity without con-
omitant GVHD. Immunization of leukemia patients
fter allogeneic stem cell transplantation (termed















































































































Bloan Kettering Cancer Center, 2003) with mHAs
ight promote GVL and reduce GVHD if appropri-
te hematopoietic-restricted mHA could be targeted
such as HA-1 or HA-2). In a recent report of 3 CML
atients who received DLI after relapse, however,
VHD occurred in each patient, albeit grade II or less
22], concomitant with an increase in HA-1–speciﬁc
r HA-2–speciﬁc CTLs and cytogenetic remission. A
ractical limit of vaccination immunotherapy with
hese mHAs is that only 10% of individuals would be
xpected to have the relevant HA-1 alternate allele, and
1%would have theHA-2 alternate allele, whichmakes
otential donor availability quite limiting.
Several investigators have used BCR-ABL pep-
ides to elicit CML-speciﬁc T-cell responses. Because
CR-ABL is present in nearly all Philadelphia chro-
osome–positive CML patients, it is thought to rep-
esent a potentially unique leukemia antigen. The
BL coding sequences upstream (5=) of exon II on
hromosome 9 are translocated to chromosome 22
nd fused in-frame with the BCR gene downstream
3=) of exon III, resulting in the most common chi-
eric messenger RNA transcript (b3a2), which is
ranslated into a chimeric protein (p210BCR-ABL).
ranslation of b3a2 messenger RNA results in the
oding of a unique amino acid (lysine) within the
usion region. Some HLA-A2–, -A3–, -A22–, and
B8–restricted overlapping peptides inclusive of this
ysine could bind to their respective HLA alleles and
ould be used to elicit T-cell proliferative responses
hen the peptide was either pulsed onto HLA-
atched normal antigen-presenting cells or onto
LA-B8–positive CML cells [23-25]. However, when
he b3a2 peptides were used to elicit b3a2-speciﬁc T
ymphocyte lines in vitro, the resulting T cells could
ot speciﬁcally lyse fresh CML cells that had not
reviously been pulsed with the peptide [25]. This
ould be due to a low afﬁnity of the peptide-speciﬁc
TL, or the peptide may not be processed or pre-
ented on CML cells. More recently, however, b3a2-
peciﬁc CTLs were identiﬁed in the peripheral blood
f chronic phase CML patients by using soluble b3a2
eptide/MHC tetramers [26]. Although the tetramer-
ositive CTLs from the patients were not examined
or their ability to kill autologous CML target cells,
3a2-speciﬁc CTL elicited in vitro from healthy do-
ors were able to kill CML cells. This suggests that
cr-abl fusion peptides may also be targets of CTL
mmunity. Further evidence by Gannage et al. [27]
hows that bcr-abl–speciﬁc CTLs can be identiﬁed in
he peripheral blood of 61% of CML patients.
To adapt what has been learned about immunity
gainst solid tumor antigens to the study of myeloid
eukemia antigens, we studied myeloid-restricted pro-
eins that are aberrantly expressed in leukemia relative
o normal hematopoietic progenitors. Myeloid leuke-
ia, like normal myeloid progenitors, expresses a t
B&MTumber of differentiation antigens associated with
ranule formation. Two examples of aberrantly ex-
ressed antigens in human leukemia are proteinase 3
PRTN3) and neutrophil elastase (ELA2), neutral serine
roteases that are stored in primary azurophil granules
nd maximally expressed at the promyelocyte stage of
ormal myeloid differentiation [28-30]. PRTN3 and
LA2 are coordinately regulated, and the transcription
actors PU.1 and C/EBP, which are responsible for
ormal myeloid differentiation from stem cells to
onocytes or granulocytes, are important in mediat-
ng their expression [31]. These transcription factors
ave been implicated in leukemogenesis [32], and
RTN3 may be important in maintaining a leukemia
henotype because PRTN3 antisense oligonucleo-
ides halt cell division and induce maturation of the
L-60 promyelocytic leukemia cell line [33]. Simi-
arly, ELA2 is overexpressed in the serum of leukemia
atients, and it preferentially suppresses normal he-
atopoietic progenitors and is involved in modulating
XCR4-mediated homing of stem cells to bone mar-
ow.
What may be critical for our ability to identify
-cell antigens in these proteins is the observation
hat PRTN3 and ELA2 are targets of autoimmune
iseases such as Wegener granulomatosis [34] and
mall-vessel vasculitis [35-37]. There is evidence for
oth T-cell and humoral immunity in patients with
hese diseases. Wegener granulomatosis is associated
ith production of cytoplasmic antineutrophil cyto-
lasmic antibodies with speciﬁcity for PRTN3 [38]. T
ells taken from affected individuals proliferate in re-
ponse to crude extracts from neutrophil granules and
o puriﬁed proteins [36,39]. These ﬁndings suggest
hat T-cell responses against these proteins might be
elatively easy to elicit in vitro by using a deductive
trategy to identify HLA-restricted peptide epitopes.
n the basis of this hypothesis, we identiﬁed PR1, an
LA-A2.1–restricted nonamer derived from both
RTN3 and ELA2, as a leukemia-associated antigen
11,40-42] by ﬁrst searching the length of the protein
ith use of the HLA-A2.1 binding motif, the most
revalent HLA allele. Peptides predicted to have
igh-afﬁnity binding to HLA-A2.1 were synthesized,
onﬁrmed to bind, and then used to elicit peptide-
peciﬁc CTLs in vitro from healthy donor lympho-
ytes. We have found that PR1 can be used to elicit
TLs from HLA-A2.1 normal donors in vitro and
hat T-cell immunity to PR1 is present in healthy
onors and in many patients with CML who are in
emission. These PR1-speciﬁc CTLs show preferen-
ial cytotoxicity toward allogeneic HLA-A2.1 my-
loid leukemia cells over HLA-identical normal donor
arrow [40]. In addition, PR1-speciﬁc CTLs inhibit
olony-forming unit granulocyte-macrophage from









































































































1LA-matched donors [41]; this suggests that leuke-
ia progenitors are also targeted.
Using PR1/HLA-A2 tetramers to detect CTLs spe-
iﬁc for PR1 (PR1-CTLs), we found a signiﬁcant cor-
elation between cytogenetic remission after treatment
ith interferon  and the presence of PR1-CTLs [11].
omewhat surprisingly, PR1-CTLs were also identiﬁed
n the peripheral blood of some allogeneic transplant
ecipients who achieved molecular remission and who
ad converted to 100%donor chimerism. PR1/HLA-A2
etramer-sorted allogeneic CTLs from patients in remis-
ion were able to kill CML cells but not normal bone
arrow cells in 4-hour cytotoxicity assays, thus demon-
trating that the PR1 self-antigen is also recognized by
llogeneic CTLs [11]. These studies established PR1 as
human leukemia–associated antigen and established
hat PR1-speciﬁc CTLs contribute to the elimination of
ML [11].
Several other HLA-restricted epitopes have been
dentiﬁed as potentially relevant leukemia-associated
ntigens. The Wilms tumor antigen 1 (WT-1) has
merged as a very potent immunogen containing mul-
iple unique HLA-restricted epitopes [43-47], and it
ay also be a marker of minimal residual disease
ecause it is aberrantly expressed in both myeloid and
ymphoid acute leukemia [48-50]. These features
ake it an attractive vaccine candidate. In addition,
he telomerase antigen human Telomerase Reverse
ranscription (hTERT) is aberrantly expressed in
eukemia and nearly all solid tumors, and hTERT-
peciﬁc CD8 T cells kill leukemia target cells. Al-
hough hematopoietic stem cells and T cells normally
xpress high levels of hTERT, they are not killed in
itro. Various surface molecules on leukemia cells,
uch as CD45, present on all hematopoietic cells, and
D33 and CD19 on myeloid and lymphoid cells,
espectively, have also been studied by deductive
eans to uncover potentially immunogenic epitopes
51-53]. Although some HLA-restricted epitopes have
een identiﬁed, it is not yet clear whether any of these
re leukemia-associated antigens. The method of se-
ologic screening of complementary DNA expression
ibraries with autologous serum (SEREX) has also
een used to identify melanoma-associated antigen
MAGE-1) and to conﬁrm WT-1 as a potential leu-
emia-associated antigen, although there may be some
ontroversy over whether the MAGE proteins are
xpressed in leukemia blasts [54].
LINICAL TRIALS
The PR1 peptide is undergoing phase I/II study,
nd the single-peptide epitope is combined with in-
omplete Freund adjuvant and granulocyte-macroph-
ge colony-stimulating factor and administered every
weeks for a total of 3 total vaccinations. Patients with v
6ML, CML, and myelodysplastic syndrome are eligi-
le, and the ﬁrst 9 patients were reported at the annual
merican Society of Hematology meeting in 2002;
atient follow-up was updated in 2004 [55]. To judge
hether a clinical response was due to the vaccine,
ligible patients were required to have progression,
elapse, or second complete remission or beyond
AML patients only) before vaccination. Immune re-
ponses, measured with PR1/HLA-A2 tetramers, were
oted in 5 patients, and clinical remissions were noted
n 4. Notably, the TCR avidity of the vaccine-induced
R1-speciﬁc CTLs was higher in the clinical respond-
rs than in the nonresponders, and durable molecular
emissions were noted in 2 patients with refractory
ML who were followed up for 8 months to nearly 3
ears. Although the trial is still ongoing, both central
nd effector memory PR1-CTLs seem critical for
uccessful vaccination and lasting immunity.
Results of early clinical trials with WT-1–derived
eptides and with BCR-ABL fusion peptides also
how very interesting results. In a heterogeneous
roup of 26 patients with AML and myelodysplastic
yndrome, immune responses were quantiﬁed by tet-
amer staining, and reductions in blasts were observed
fter 2 to 3 peptide vaccinations of WT-1 peptides
lus adjuvant given every 2 weeks [56]. Although
any patients in this trial were treated in hematologic
emission, a reduction in the amount of WT-1 tran-
cript, measured by PCR, correlated with immune
esponse. Immunity to BCR-ABL peptides has also
een elicited in clinical trials. By immunizing CML
atients with 6 different b3a2 fusion peptides plus
djuvant, immune responses were noted in all 14 pa-
ients, although clinical efﬁcacy could not be clearly
stablished [57]. In another, more recent, trial, 17
atients with CML were given 6 vaccinations of b3a2
usion region peptides plus adjuvant, and immune
esponses were measured by enzyme-linked Immuno-
POT (ELISPOT) or tetramer. The patients had
table residual disease that could be measured by stan-
ard cytogenetics or quantitative PCR after treatment
ith imatinib or interferon-. Complete cytogenetic
emission was observed in 7 patients after vaccination,
lthough the patients continued to receive imatinib or
nterferon . Nevertheless, peptide-speciﬁc immune
esponses were noted in these patients, and they were
ssociated with clinical responses [58].
ONCLUSIONS
In summary, an increased understanding of the
ritical elements in T-cell immunity against leukemia
as led to the identiﬁcation of a handful of candidate
eukemia antigens. In preliminary clinical trials, PR1,











































Bant to note that patients who experience clinical ben-
ﬁt are those with minimal disease who may have an
ntact T-cell repertoire with the potential to recognize
he peptide antigen/MHC. This observation may in
art explain why peptide vaccination of leukemia may
old greater potential than similar vaccine strategies
or solid tumors, where objective responses are ob-
erved in 3% of patients overall, because sensitive
CR-based measurements that establish minimal re-
idual disease in leukemia patients provide a window
f opportunity for vaccination. Furthermore, because
he malignant cells and the potential immune re-
ponder cells reside within the same primary and sec-
ndary lymphatic organs, T cells do not need to trafﬁc
o distant tumor sites to ﬁnd and kill the leukemia
ells. It will be important to conﬁrm whether vaccines
old potential as part of the therapy of leukemia by
onducting randomized trials with proper immune
onitoring that can establish vaccine-induced immu-
ity. In the future, combination therapy with targeted
mall molecules, viewed mostly as drugs that target
ritical molecular pathways in malignant cells, may
lso include vaccine antigens.
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